VAM
OREX

Visium Asset Management’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Visium Asset Management’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-12,540
Closed -$534K – 1358
2014
Q3 		$534K Buy
+12,540
New +$673K 0.01% 756
2013
Q4 		– Sell
-61,560
Closed -$3.78M – 1096
2013
Q3 		$3.78M Sell
61,560
-105,440
-63% -$7.14M 0.09% 178
2013
Q2 		$9.77M Buy
+167,000
New +$10.3M 0.23% 79

Other funds holding OREX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Visium Asset Management's OREX Position: Q4 2014 in Review

Visium Asset Management sold out of Orexigen Therapeutics, Inc. (OREX) in Q4 2014, closing a stake of 12,540 shares — an estimated $534K sold.

Visium Asset Management first reported a position in OREX in Q2 2013 and held it in 3 quarters. The position peaked at $9.77M in Q2 2013. 147 funds tracked by Wall St. Rank hold OREX as of Q4 2014.

  • Visium Asset Management reported no remaining Orexigen Therapeutics, Inc. position as of Q4 2014 after selling out during the quarter.
  • Visium Asset Management sold 12,540 Orexigen Therapeutics, Inc. shares in Q4 2014, an estimated $534K.
  • Visium Asset Management first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 3 quarters.
  • Visium Asset Management's Orexigen Therapeutics, Inc. position peaked at $9.77M in Q2 2013.
  • 147 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q4 2014.

Based on Visium Asset Management's 13F filing for Q4 2014, filed 13 Feb 2015.